Kineta, Inc. is a Delaware-incorporated biopharmaceutical company focused on developing therapies for immune-related and inflammatory diseases, with collaborations and a focus on long-term value creation.

# Company Summary: Kineta, Inc.

## Overview
- **Legal Name:** Kineta, Inc.
- **Incorporated in:** Delaware
- **Headquarters:** Mercer Island, Washington, 7683 SE 27th Street, Suite 481
- **Telephone:** (206) 378-0400
- **Stock Listing:** Common Stock traded on OTC Pink Market under the ticker **KANT**

## Business Focus
- Kineta is a **biopharmaceutical company** specialized in developing therapies for immune-related and inflammatory diseases.
- The company's research and development efforts are focused on novel immuno-oncology, infectious diseases, and autoimmune disorders.

## Company Operations
- **Employees:** Specific number of employees not provided.
- **Customers:** No specific information on the number of customers.
- **Revenue & Income:** No financial figures related to revenue or net income are provided in the filing.
- **Clientele:** Not specified; the company appears to engage primarily in research, development, and partnerships rather than direct sales to consumers or large customer bases.

## Strategic and R&D Focus
- The company emphasizes long-term value creation through **long-term equity incentives**, with a pay-for-performance compensation philosophy.
- Kineta engages in various collaborations, licensing agreements, and technology licenses, such as with GigaGen, Samsung Biologics, and others to support its R&D efforts.

## Regulatory & Corporate Structure
- **SEC Filings:** Filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and an amendment (Form 10-K/A).
- **Market Capitalization:** As of June 30, 2024, the market value of its stock held by non-affiliates was approximately **$2.5 million**.
- **Shares Outstanding:** 13,540,355 shares of common stock as of April 25, 2025.

*Note: The document primarily covers corporate governance, executive compensation, and detailed contractual arrangements, with minimal explicit financial data on revenue, customers, or income.*

Kineta, Inc. is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer.

# Kineta, Inc. Overview

## Company Profile
Kineta, Inc. is a clinical-stage biotechnology company focused on developing next-generation immunotherapies targeting cancer and immune resistance mechanisms. Established in 2006 and based in Mercer Island, Washington, Kineta specializes in innovative biopharmaceutical research, with a mission to transform patients' lives through its advanced immunotherapy pipeline.

## Key Areas of Focus
- **Cancer Immunotherapy**: Kineta's primary focus is on harnessing the body's immune system to fight cancer through the development of fully human monoclonal antibodies.
- **Mechanisms Addressed**:
  - **Immunosuppression** in the tumor microenvironment (TME)
  - **Exhausted T cells** 
  - **Poor tumor immunogenicity**

### Product Candidates
1. **KVA12123**
   - **Type**: Monoclonal antibody (mAb) targeting VISTA (V-domain Ig suppressor of T cell activation).
   - **Stage**: Currently in Phase 1/2 clinical trials, initiated in April 2023.
   - **Indications**: Evaluated for treatment in advanced solid tumors including non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and ovarian cancer (OC).

2. **Anti-CD27 Agonist mAb**
   - Designed to combat exhausted T cells, with preclinical candidates currently under study.

## Workforce
- Kineta had **11 full-time employees** as of December 31, 2023, including **3 with Ph.D. degrees** and **1 with an M.D. degree**.
- The company's workforce was reduced by **approximately 64%** in February 2024 as part of a corporate restructuring effort.

## Financial Overview
- As of **December 31, 2023**:
  - **Cash Position**: $5.8 million
  - **Revenue**: Kineta has **not generated any revenue from product sales** as of the specified date.
  - **Net Loss**: $14.1 million for the year ended December 31, 2023.
  - **Accumulated Deficit**: Approximately **$165.8 million**.

## Clinical Trials and Research
- The ongoing **VISTA-101 clinical trial** is evaluating KVA12123 both as a monotherapy and in combination with pembrolizumab (KEYTRUDA®).
- Initial results from the clinical trials indicated that KVA12123 was well-tolerated and demonstrated a promising safety profile, with no significant adverse effects reported.

## Market Position
- Kineta operates within the immuno-oncology market, which generated approximately **$111 billion in sales in 2023** and is expected to reach **$201 billion by 2028**.
- If successful, KVA12123 is expected to target markets representing an estimated **$48 billion opportunity by 2027** for indications including NSCLC, CRC, and OC.

## Challenges Ahead
- Kineta faces significant risks regarding further funding, regulatory approvals, and competition within the biopharmaceutical industry.
- The company has identified substantial doubts regarding its ability to continue as a going concern, pending successful funding or strategic transactions.

As of now, Kineta aims to explore strategic alternatives to maximize shareholder value, which may include asset sales or seeking partnerships to aid in the development of its product pipeline.

KINETA, INC./DE

10-K / April 29, 2025

10-K / March 21, 2024

10-K / April 29, 2025

Company Summary: Kineta, Inc.

Overview

Business Focus

Company Operations

Strategic and R&D Focus

Regulatory & Corporate Structure